Diabetes drug may shield breast cancer patients from uterine thickening
NCT ID NCT07145827
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at whether metformin, a common diabetes drug, can reduce the thickening of the uterine lining caused by tamoxifen in postmenopausal breast cancer survivors. Sixty women who had been taking tamoxifen for at least a year were given either metformin or a placebo for 12 months. Researchers measured their endometrial thickness with ultrasound at regular visits to see if metformin made a difference.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
metformin
What this could lead to
If it works, this could offer a way to manage a common side effect of tamoxifen, potentially reducing the risk of endometrial cancer in breast cancer survivors.
What could go wrong
This is a small, completed trial with only 60 participants. The results may not apply to all patients, and metformin can cause gastrointestinal side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baghdad Medical City / Department of Oncology
Baghdad, Baghdad Governorate, 10045, Iraq